Here are four highlights:
1. Operating expenses for the third quarter were $2.1 million, compared to $6.3 million in the third quarter of 2017.
2. InVivo anticipates it will continue to maintain its current cash burn rate of less than $1 million per month, including expenses related to clinical studies.
3. The company reported a $3.2 million net loss for the quarter, compared to the $9.4 million net loss in the third quarter of 2017.
4. InVivo ended the quarter with $19.7 million of cash and cash equivalents.
To view the full financial report, click here.
More articles on biologics:
Imagion Biosystems incorporates ‘printer & ink’ business model for medical imaging
SpinalCyte receives additional patents: 3 takeaways
3 things to know about Lattice Biologics’ CEO
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
